Beyond Immunomodulatory Drugs: Next-Generation Cereblon Modulators in Multiple Myeloma. (PubMed, Cancer J) - Sep 30, 2026 - "More recently, cereblon E3 ligase modulators (CELMoDs), such as iberdomide and mezigdomide, have emerged as next-generation cereblon-targeting agents with enhanced potency, deeper substrate degradation, and activity in lenalidomide- and pomalidomide-resistant settings. In parallel, novel degraders such as cemsidomide have shown encouraging preliminary activity, further expanding the therapeutic potential of cereblon-directed approaches in MM. In this review, we aim to summarize the evolution of oral therapies in MM, focusing on the efficacy and safety of next-generation cereblon modulators and emerging cereblon-directed degraders."
Journal • Review • Hematological Malignancies • Multiple Myeloma • Oncology • Targeted Protein Degradation • CRBN
|
|
Lorenzo Cani; Roberto Mina; Sagar Lonial
|